CAS: 477-57-6; 16,36,37,54-Tetramethoxy-12,32-Dimethyl-11,12,13,14,31,32,33,34-Octahydro-2,6-Dioxa-1(7,1),3(8,1)-Diisoquinolina-5(1,3),7(1,4)-Dibenzenacyclooctaphane

上下游产品

CAS号1472-62-4 N-甲基衡州乌药碱 | CAS号17934-80-4 (+/-)-1-(4-hydr... | CAS号66277-16-5 didehydro-N-met... | CAS号186581-53-3 重氮甲烷 | CAS号436-77-1 防己诺林碱; 粉防己乙素; 汉... | CAS号3423-07-2 1α-(4-Hydroxybe... | CAS号479-37-8 16H-1,24:6,9-Di...

📜(+/-)-1-(4-Hydroxybenzyl)-7-Hydroxy-6-Methoxy-1,2,3,4-Tetrahydroisoquinoline Hydrochloride置于酒石酸体系中,用 水,二甲基亚砜 作为反应溶剂,化学反应 168.0H,反应生成 异汉防己甲素
参考文献:异粉防己碱的生物合成
标题:异粉防己碱的生物合成
摘要:将(+/-)-香豆碱,(+/-)-N-甲基可尿酸,二氢-N-甲基碘化氢碘化物,(+)-(S)-N-甲基可尿酸和(-)-(R)-N-甲基可尿酸掺入异粉防己碱中研发了球果小球藻dc,并证明了(+/-)-,(+)-(S)-和(-)-R-N-甲基coclaurines和二氢-N-甲基碘化钴的特定用途.证据支持(+)-(S)-和(-)-(R)-N-甲基coclaurines的分子间氧化偶合反应形成异粉防己碱.双标记实验用(+/-)-N-[14 C]甲基〔1-3H] Coclaurine证明n-甲基coclaurine中不对称中心的氢原子保留在生物转化为异粉防己碱中.
DOI:10.1016/0040-4020(80)80107-4

专利信息

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-2024239805-A1
优先权日:2022-12-16
标 题:Aza-yang cyclization-buchner aromatic ring expansion: collective synthesis of cycloheptatriene-containing azetidine lactones
发明人：SINGH MANVENDRA PAL; BOSKOVIC ZARKO; GASKINS BRYCE
权利人:UNIV KANSAS
摘要:The present disclosure is directed to a compound of Formula I, Formula II, Formula III, Formula IV, or Formula Vor a pharmaceutically acceptable salt and/or solvate thereof.

专利号:US-5171676-A
优先权日:1991-10-31
标 题 :Method of introducing hydroxyl groups into artemisinin and its derivatives
发明人：ZIFFER HERMAN; HU YULIN
权利人:US HEALTH
摘要:The fungus Beauveria sulfurescens has been employed to introduce hydroxyl groups into artemisinin and derivatives of artemisinin, an antimalarial. Hydroxylated derivatives of artemisinin and derivatives of artemisinin produced thereby possess antimalarial activity, and can serve as intermediates in the synthesis of further derivatives useful in treating malaria.

专利号:US-2024287041-A1
优先权日:2021-05-20
标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
发明人：BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.